Safety and efficacy of the blood-stage malaria vaccine RH5.1/ Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children

This paper of the day published in the Lancet says that people in Burkina Faso who took part in a Phase 2b study of a new malaria vaccine called RH5.1/Matrix-M showed positive results. The vaccine, which demonstrated a good safety profile and had high antibody reactions, proved safe and effective for children aged 5 to 17 months. The delayed third-dose schedule performed better than the monthly schedule against clinical malaria. The children who study this disease are still getting very ill and dying from malaria, but these results give us much-needed hope for a tool to combat malaria.